individuals prognostic tests identified overall, -/+ HDAA, groups with median survivals of 15.5 -24 mos. HDAA did not significantly reduce survival. Severe AEs range from 0-< 5% in HDAA groups. Favorable S trends were attributable to Taxanes, % females and A.L.A.N. cell ratios. The latter are putative surrogate markers of immune function. Unexpectedly, contrary to clinical characteristics, and referring physician expectations, the majority of patients had up to 75% favorable prognostic tests.
Conclusion:All comparisons, -/+ HDAA, found no decrease in palliative S. All S end points results: median, 25th percentile, 12 and 24 mos, encourage broad treatment, regardless of resistance and age. The A.L.A.N. score and its elements defined S subsets. HDAA is safe with the GFLIO drugs in moderate dosages. Further phase II/III clinical trials are recommended.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.